Results 31 to 40 of about 84,926 (204)

Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines

Frontiers in Pharmacology, 2022
Antiplatelet therapy, mainly consisting of aspirin and P2Y12 receptor antagonists, is the cornerstone of the pharmacological treatment and prevention of atherothrombotic diseases.
Georges Jourdi, Georges Jourdi, Guillaume Marquis-Gravel, Guillaume Marquis-Gravel, Anne-Céline Martin, Anne-Céline Martin, Marie Lordkipanidzé, Marie Lordkipanidzé, Anne Godier, Anne Godier, Pascale Gaussem, Pascale Gaussem   +11 more
doaj   +1 more source

rLOAD: does sex mediate the effect of acute antiplatelet loading on stroke outcome. [PDF]

, 2014
BackgroundBiologic sex can influence response to pharmacologic therapy. The purpose of this proof-of-concept study was to evaluate the medicating effects of estrogen in the efficacy of acute antiplatelet loading therapy on stroke outcome in the rabbit ...
Compton, M Peggy, Eastwood, Jo-Ann, Gylys, Karen, Meyer, Dawn M, Zivin, Justin A   +4 more
core   +3 more sources

ANTITHROMBOTIC THERAPY AT AN ATRIAL FIBRILLATION: OLD PROBLEMS AND NEW SOLUTIONS

Рациональная фармакотерапия в кардиологии, 2016
The problem of antiplatelet drug choice in patients with atrial fibrillation is discussed. Authors give special attention to new alternative drugs for prevention of thrombotic complications apart from old known antiplatelet drugs.
M. Yu. Gilyarov, V. A. Sulimov
doaj   +1 more source

Multimodal interventions to enhance adherence to secondary preventive medication after stroke: a systematic review and meta-analyses [PDF]

, 2016
Summary: Introduction: Nonadherence to secondary preventative medications after stroke is common and is associated with poor outcomes. Numerous strategies exist to promote adherence.
Al AlShaikh, Sukainah, Dawson, Jesse, Dunn, William, Quinn, Terry, Walters, Matthew   +4 more
core   +1 more source

ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY

Рациональная фармакотерапия в кардиологии, 2017
Current guidelines for the management of atrial fibrillation (AF) recommend using anticoagulants as first-line drugs for stroke prevention, but in real medical practice antiplatelet drugs are often prescribed to elderly patients.
E. А. Ushkalova, S. K. Zyryanov, E. V. Dumchenko   +2 more
doaj   +1 more source

A hopeful therapy for Niemann-Pick C diseases [PDF]

, 2017
Not abstract ...
Erickson, Robert P., Fiorenza, Maria Teresa   +1 more
core   +1 more source

RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE

Рациональная фармакотерапия в кардиологии, 2015
The clinical, cell and genetic factors are distinguished among reasons for resistance to antiplatelet drugs. There are many methods to detect sensitivity to antiplatelet drugs, but they all have disadvantages.
D. H. Aynetdinova, A. E. Udovichenko, V. A. Sulimov   +2 more
doaj   +3 more sources

Progress Analysis of Personalized Antiplatelet Therapy in Patients with Coronary Heart Disease Undergoing Interventional Therapy

Reviews in Cardiovascular Medicine
Coronary atherosclerosis (or coronary heart disease [CHD]) is a common cardiovascular disease that seriously damages human health. Percutaneous coronary stent implantation represents the primary treatment option for severe CHD in clinical practice ...
Ji-tong Yang, Qiu-juan Zhang, Hua Li, Ming-wei Liu   +3 more
doaj   +1 more source

Antiplatelet drugs and the perioperative period: What every urologist needs to know

Indian Journal of Urology, 2009
Antiplatelet agents like aspirin and clopidogrel are widely used for indications ranging from primary and secondary prevention of myocardial infarction or stroke to prevention of coronary stent thrombosis after percutaneous coronary interventions.
Pawan Vasudeva, Apul Goel, Vengetesh K Sengottayan, Satyanarayan Sankhwar, Divakar Dalela   +4 more
doaj   +1 more source

PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS

Фармация и фармакология (Пятигорск), 2021
Cardiovascular diseases (CVDs) are the leading cause of disability and mortality worldwide. Increased thrombosis is the trigger point for the development of various CVDs and their complications, and therefore, therapy with P2Y12-receptor inhibitors is ...
B. I. Kantemirova, E. A. Orlova, O. S. Polunina, E. N. Chernysheva, M. A. Abdullaev, D. A. Sychev   +5 more
doaj   +1 more source